FDA 483 - Lancaster Junction Farm - March 10, 2011

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified four key deficiencies related to the facility's quality system and manufacturing processes.

Observation 1 indicates the firm failed to establish adequate procedures for the cleaning and maintenance of equipment. This suggests a potential risk of cross-contamination or product degradation due to improperly maintained machinery.

Observation 2 states the firm did not adequately validate the manufacturing process for Drug X. This is a critical finding as process validation ensures that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. Lack of adequate validation raises concerns about the consistent quality and safety of Drug X.

Observation 3 notes the firm did not have proper controls in place to prevent contamination of products. This broad observation points to potential issues across various stages of manufacturing, including raw material handling, in-process controls, and finished product storage, all of which could lead to compromised product integrity.

Finally, Observation 4 highlights that the firm did not maintain proper records of batch production and control. Accurate and complete batch records are essential for traceability, quality control, and investigation of deviations. Their absence or inadequacy impedes the ability to ensure product quality and investigate potential issues.

Collectively, these observations indicate significant deficiencies in the firm's quality management system, particularly concerning equipment maintenance, process validation, contamination control, and record-keeping, which have direct implications for product quality, safety, and regulatory compliance.